Related Experiment Video
Updated: Dec 11, 2025

Analysis of Retinoic Acid-induced Neural Differentiation of Mouse Embryonic Stem Cells in Two and Three-dimensional Embryoid Bodies
Published on: April 22, 2017
Retinoic acid receptor-targeted drugs in neurodegenerative disease
Jason Nicol Clark1, Andrew Whiting2, Peter McCaffery1
1School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen , Aberdeen, Scotland, UK.
Introduction:
Neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by progressive neuronal loss and currently lack effective treatments that block the degenerative process. It has been suggested that retinoids, a class of vitamin A-derived compounds, may hold potential as future therapeutics for these disorders.
Areas Covered:
In this review, we explore the role of retinoids in modulating various signaling pathways in the brain which influence pathologically relevant processes such as cellular differentiation, immune and antioxidant response, neurite outgrowth and neurite regeneration. These actions are predominantly mediated by the retinoic acid receptors and we discuss the developmental history of ligands for these receptors, assessing how refinements in receptor binding specificity and improved pharmacokinetic properties may influence the management of off-target effects.
Expert Opinion:
New approaches to understanding retinoid's mechanisms of action, including non-genomic pathways, and how these mechanisms interact may prove vital in the development of future retinoid-based neurodegenerative disease treatments.
Related Concept Videos
Alzheimer's Disease: Treatment
Drugs Affecting Neurotransmitter Synthesis
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Drugs Affecting Neurotransmitter Release or Uptake
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

